% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • beachbumsoon325 beachbumsoon325 Oct 22, 2013 3:10 PM Flag

    8K filed

    The combination study with TH-302 plus pazopanib was conducted in 30 patients with a variety of solid tumors for whom standard therapy or palliative measures were nonexistent or no longer effective. The clinical benefit rate was 76% (n=25 evaluable patients) with three patients with partial responses (12%) and 16 patients with stable disease (64%). The partial responses were observed in patients with neuroendocrine cancer, ovarian cancer, and chondrosarcoma.

    76 percent clinical benefit rate with 64 percent of mostly terminal patients reaching stable disease. The great news keeps on coming in and the stock price stays the same . Red on a daily basis, but not going down. Games games and more games.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.5829-0.0370(-5.97%)Jun 29 4:00 PMEDT